A multicentric, randomized, controlled trial was conducted to evaluate the safety and efficacy of centhaquine as an adjuvant to the standard of care in hypovolemic shock patients.

Fifty patients were randomized 1:1 to receive centhaquine or saline. Centhaquine was administered at a dose of 0.01 mg/kg in 100 ml saline and infused over 1 h. The control group received 100 ml of saline over a 1-h infusion.

Centhaquine was safe and well tolerated. There were no drug-related adverse events in the study.

Centhaquine improved blood pressure, reduced blood lactate levels, and improved base deficit. The total amount of vasopressors needed was lower in the centhaquine group than in the control group. Multiple organ dysfunction syndrome (MODS) score and acute respiratory distress syndrome (ARDS) also improved with centhaquine.

Although the sample size is small, most of the parameters indicate that centhaquine is likely to be a safe and effective resuscitative agent.